{"schema":"sb.node.v1","id":"sb:e/37f433e31cef053c2eae3953","kind":"entity","label":{"text":"dana-farber cancer institute","locale":"en"},"identity":{"anchor":"label:en:dana-farber cancer institute","strength":"label"},"asOf":{"knowledgeCutoff":"2026-10-08T15:58:04.276991+00:00","snapshot":"deploy dd8fb6da4473490c71337bbbe1a399a6a221fac3"},"lens":{"kind":"public"},"build":{"plane":"projected","builtFrom":["entity_graph.slim.json","entity_receipts (deploy asset)","event_graph.json","truth_records (deploy asset)","corroborated_record.json"],"rule":"node-projection.entity@v1"},"standing":{"evidence":{"supporting":27,"separatePublishers":14,"basis":"documents that mention the subject and the outlets that carried them; a mention is evidence the referent is in use, not evidence about any claim"},"admission":{"state":"canonical","reason":"entity graph provenance 'curated'; the node carries no promotion receipt in v1","policy":"EQ-PROMOTION (receipt not carried)"},"disposition":{"state":"served","reason":"public record"},"validity":{"from":"2026-08-31","to":"2026-10-05","basis":"first and last day we saw it mentioned; not the subject's own lifetime"},"measurement":{"state":"partial","blind":["assertion coverage 0: about 100% of mentions carry no typed assertion"]}},"dimensions":{"domains":["society_news","auto","precision_medicine"],"activeDays":19,"assertions":{}},"up":[],"upNote":"An entity is a root: it is contained by nothing. Pan out by following R.","children":{"count":12,"byKind":{"observation":12},"items":[{"id":"sb:o/c77871b44ad733bf723e3645","kind":"observation","label":"The Medical News · 2026-10-05 · Dana-Farber research reveals possible new target for treatment of sickle cell and beta thalassemia","url":"https://www.news-medical.net/news/20261005/Dana-Farber-research-reveals-possible-new-target-for-treatment-of-sickle-cell-and-beta-thalassemia.aspx"},{"id":"sb:o/0477f33f1f92913ab49329a4","kind":"observation","label":"Financial Post · 2026-10-04 · Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026","url":"https://financialpost.com/pmn/business-wire-news-releases-pmn/agenus-reports-48-estimated-three-year-survival-with-botbal-in-recurrent-ovarian-cancer-at-igcs-2026"},{"id":"sb:o/a12cafacdc03603f0feb3313","kind":"observation","label":"GEN · 2026-10-02 · Talus Bio’s Structure-Free AI Model Targets Unstructured Proteins in Their Native Cellular Context","url":"https://www.genengnews.com/topics/artificial-intelligence/talus-bios-structure-free-ai-model-targets-unstructured-proteins-in-their-native-cellular-context/"},{"id":"sb:o/901df94790a9c91573864ae0","kind":"observation","label":"The ASCO Post · 2026-10-02 · Advanced Lung Cancer Pumitamig Plus Elfetabart Drozuntecan","url":"https://ascopost.com/videos/iaslc-wclc-2026/advanced-lung-cancer-pumitamig-plus-elfetabart-drozuntecan/"},{"id":"sb:o/e7f192ca5c1a7ae7fcc55b5d","kind":"observation","label":"The ASCO Post · 2026-09-30 · Targeting B7-H3 in Second-Line SCLC Treatment Novel ADCs","url":"https://ascopost.com/videos/iaslc-wclc-2026/targeting-b7-h3-in-second-line-sclc-treatment-novel-adcs/"},{"id":"sb:o/0b190ae571737b3627644570","kind":"observation","label":"Medical Daily · 2026-09-29 · Splitting Brain Radiosurgery into Three to Five Sessions After Tumor Removal Lowered Recurrence in 242-Patient Trial","url":"https://www.medicaldaily.com/fractionated-radiosurgery-brain-metastases-recurrence-trial-479233"},{"id":"sb:o/9eecd1367dbc3cab989ed336","kind":"observation","label":"New York Post · 2026-09-29 · She was ready to die. Now she’s in remission — cancer vaccines could be the next big thing in medicine","url":"https://nypost.com/2026/09/29/health/cancer-vaccines-could-be-the-next-big-thing-in-medicine/"},{"id":"sb:o/872fe75bc02707fa00730ce2","kind":"observation","label":"The ASCO Post · 2026-09-29 · Mobile Lung CT Screening in Resource-Limited Settings BRELT3","url":"https://ascopost.com/videos/iaslc-wclc-2026/mobile-lung-ct-screening-in-resource-limited-settings-brelt3/"},{"id":"sb:o/92aa42c5b305b288f397378f","kind":"observation","label":"Quantum Zeitgeist · 2026-09-28 · Zapata Quantum’s Sumit Kapur joins Boston’s Power 50 leaders","url":"https://quantumzeitgeist.com/zapata-quantums-sumit-kapur-joins/"},{"id":"sb:o/d531ca6fb144412999cfbcf3","kind":"observation","label":"The ASCO Post · 2026-09-24 · SCLC Tarlatamab Extended-Interval Dosing Regimens","url":"https://ascopost.com/videos/iaslc-wclc-2026/sclc-tarlatamab-extended-interval-dosing-regimens/"}],"cursor":"c1.eyJpZCI6InNiOmUvMzdmNDMzZTMxY2VmMDUzYzJlYWUzOTUzIiwibCI6ImNoaWxkcmVuIiwibyI6MTAsImsiOm51bGwsImEiOiIyMDI2LTEwLTA4VDE1OjU4OjA0LjI3Njk5MSswMDowMCJ9","order":"newest first; we keep the 12 newest receipts for this entity. Its other observations are counted in standing.evidence.supporting but are not addressable in v1"},"relations":{"count":10,"byKind":{"co-mentioned":10},"items":[{"kind":"relation","label":"co-mentioned with lung cancer (13 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/7938627ec06d63c84198485a"},{"kind":"relation","label":"co-mentioned with cancer center (11 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/aef1f072b9d1297cee6f9e52"},{"kind":"relation","label":"co-mentioned with iaslc (10 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/57f422c0d1ebfec712217a82"},{"kind":"relation","label":"co-mentioned with wclc (10 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/204dc5f495777192f8b01944"},{"kind":"relation","label":"co-mentioned with egfr (10 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/c62af830787bc7d4fcb8d32f"},{"kind":"relation","label":"co-mentioned with egfr-mutated (9 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/a53d348b47b7c7e559ffb25b"},{"kind":"relation","label":"co-mentioned with her2 (9 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/ba636c4986e307a1ba7306a5"},{"kind":"relation","label":"co-mentioned with her2-directed (9 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/07644a3e0d1fb487a927055c"},{"kind":"relation","label":"co-mentioned with her2-mutant (9 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/a83e093d7b6cabb2e18aa5a8"},{"kind":"relation","label":"co-mentioned with t-dxd (8 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/8504fa0db7f77ab3630e520a"}],"cursor":null,"order":"situations first, then claims (the subject's own maintained record, then site-wide corroborated clusters; each label ends with its standing), then co-mentions by shared documents, descending. Co-mentions are the ten strongest the entity graph keeps per entity"},"edge":{"state":"continues"},"links":{"rest":"/api/v1/node/e/37f433e31cef053c2eae3953","mcp":"traverse {\"id\":\"sb:e/37f433e31cef053c2eae3953\"}","page":"/entity/dana-farber-cancer-institute/"},"limits":{"levelsPerCall":1,"pageSize":10,"maxPageSize":50,"membersMax":50,"statement":"One level per call: depth is 1 and only 1, and there is no whole-graph dump. pageSize 1-50 (default 10); a page limit is a cursor, never an edge. Members are listed up to 50. At most 60 traverse calls a minute per caller (runaway-loop protection, not a meter). One knowledge cutoff is served: the deploy's."},"actions":[{"verb":"unfold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/37f433e31cef053c2eae3953\",\"level\":\"children\"}"},{"verb":"fold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/37f433e31cef053c2eae3953\"}"},{"verb":"panOut","lit":false,"effect":"read","layer":"cantina","reason":"An entity is a root: it is contained by nothing. Pan out by following R."},{"verb":"follow","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/37f433e31cef053c2eae3953\",\"level\":\"relations\"}"},{"verb":"receipts","lit":false,"effect":"read","layer":"cantina","reason":"receipts are the observations below this node; unfold to reach them"},{"verb":"edge","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/37f433e31cef053c2eae3953\"}"},{"verb":"asOf","lit":false,"effect":"read","layer":"cantina","reason":"v1 serves one knowledge cutoff, this deploy's; walking an earlier cutoff needs retained history (EQ-REPLAY), which v1 does not keep"},{"verb":"switchObserver","lit":false,"effect":"read","layer":"cantina","reason":"the public record is the same for every observer; traversal through a Watch's lens is not served in v1"},{"verb":"readOriginal","lit":false,"effect":"read","layer":"cantina","reason":"no translation is applied on this node; every label is the source's own text"},{"verb":"save","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"saving applies to a configured Watch; configure one around this node first (free), then save it"},{"verb":"deliver","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"delivery applies to a saved Watch"},{"verb":"format","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"output format applies to a saved Watch"},{"verb":"deltaR","lit":false,"effect":"read","layer":"workshop","reason":"Delta R needs a saved Watch with a previous reading"},{"verb":"read","lit":false,"effect":"read","layer":"docking-bay","reason":"one-time Reads are parked until the Commander decides their shape (#938)"}]}